Next Article in Journal / Special Issue
Trends in Personalized Therapies in Oncology: The (Venture) Capitalist’s Perspective
Previous Article in Journal / Special Issue
Developing Drugs for Children and the Adjustment of Medication—Is It a New Challenge or an Adaptation of Past Ideas?

Personalized Medicine and Cancer

Epidemiology and Genetics Research Program (EGRP), Division of Cancer Control and Population Sciences, National Cancer Institute (NCI), National Institutes of Health (NIH), 6130 Executive Boulevard, Rockville, MD 20852, USA
J. Pers. Med. 2012, 2(1), 1-14;
Received: 1 January 2012 / Revised: 18 January 2012 / Accepted: 21 January 2012 / Published: 30 January 2012
(This article belongs to the Special Issue Recent Advances in Personalized Medicine)
Cancer is one of the leading causes of death in the United States, and more than 1.5 million new cases and more than 0.5 million deaths were reported during 2010 in the United States alone. Following completion of the sequencing of the human genome, substantial progress has been made in characterizing the human epigenome, proteome, and metabolome; a better understanding of pharmacogenomics has been developed, and the potential for customizing health care for the individual has grown tremendously. Recently, personalized medicine has mainly involved the systematic use of genetic or other information about an individual patient to select or optimize that patient’s preventative and therapeutic care. Molecular profiling in healthy and cancer patient samples may allow for a greater degree of personalized medicine than is currently available. Information about a patient’s proteinaceous, genetic, and metabolic profile could be used to tailor medical care to that individual’s needs. A key attribute of this medical model is the development of companion diagnostics, whereby molecular assays that measure levels of proteins, genes, or specific mutations are used to provide a specific therapy for an individual’s condition by stratifying disease status, selecting the proper medication, and tailoring dosages to that patient’s specific needs. Additionally, such methods can be used to assess a patient’s risk factors for a number of conditions and to tailor individual preventative treatments. Recent advances, challenges, and future perspectives of personalized medicine in cancer are discussed. View Full-Text
Keywords: cancer; diagnosis; epigenome; genome; metabolome; personalized medicine; outcome; proteome; survival; treatment cancer; diagnosis; epigenome; genome; metabolome; personalized medicine; outcome; proteome; survival; treatment
MDPI and ACS Style

Verma, M. Personalized Medicine and Cancer. J. Pers. Med. 2012, 2, 1-14.

AMA Style

Verma M. Personalized Medicine and Cancer. Journal of Personalized Medicine. 2012; 2(1):1-14.

Chicago/Turabian Style

Verma, Mukesh. 2012. "Personalized Medicine and Cancer" Journal of Personalized Medicine 2, no. 1: 1-14.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop